Correlation of NK cell activity against autologous tumour cells and K562 cells with the clinical outcome during therapy with mistletoe extracts;Zusammenhang der NK-zellaktivität gegen autologe tumor- und K562-zellen mit dem klinischen verlauf unter misteltherapie

Forschende Komplementarmedizin

Volumn 13, Issue 3, 2006, Pages 147-155

  Schink, Michael ^a,f   Tröger, Wilfried ^b   Goyert, Andreas ^c   Scheuerecker, Heinz ^d   Selbmann, Hans Konrad ^e   Glaser, Florian ^d  

^a Forschungsabteilung   (Germany)

^b Klinische Forschung Dr Tröger   (Germany)

^c Abteilung fur Innere Medizin   (Germany)

^d Chirurgische Abteilung   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f Verein Filderklinik eV   (Germany)

Author keywords

Autologous tumour cells; Clinical trial; K562 cells; Mistletoe therapy; NK cell activity; Quality of life; Relapse

Indexed keywords

VISCUM ALBUM EXTRACT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL CIRCULATION; PROGNOSIS; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

AGED; BREAST NEOPLASMS; COHORT STUDIES; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; FEMALE; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MISTLETOE; PHYTOTHERAPY; PLANT EXTRACTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33745762375     PISSN: 16614119     EISSN: 16614127     Source Type: Journal    
DOI: 10.1159/000092624     Document Type: Article

References (37)

1. Berg PA, Stein GM: Beeinflusst die Misteltherapie die Abwehr epithelialer Tumoren? Eine kritische immunologische Analyse. Dtsch Med Wochenschr 2001;126:339-345.
2. Whiteside TL, Herberman RB: The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 1995;7:704-710.
3. Barlozzari T, Reynolds CW, Herberman RB: In vivo role of natural killer cells: Involvement of large granular lymphocytes in the clearence of tumor cells in anti-asialo GM1-treated rats. J Immunol 1983;131:1024-1027.
4. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM: In vivo natural killer cell activities revealed by natural killer cell-deficient mice. PNAS 2000;97:2731-2736.
5. Hajto T, Hostanska K: An investigation of the ability of Viscum album-activated granulocytes to regulate natural killer cells in vivo. Clin Trials J 1986;23:345-358.
6. Hajto T, Lanzrein C: Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology 1986;43:93-97.
7. Hamprecht K, Handgretinger R, Voetsch W, Anderer FA: Mediation of human NK-activity by components in extracts of Viscum album. Int J Immunopharmacol 1987;9:199-209.
8. Huelsen H, Kron R, Mechelke F: Influence of Viscum album preparations on the natural killer cell-mediated cytotoxicity of peripheral blood. Naturwissenschaften 1989;76:530-531.
9. Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975;45:321-334.
10. Uchida A, Kariya Y, Okamoto N, Sugie K, Fujimoto T, Yagita M: Prediction of postoperative clinical course by autologous tumor-killing activity in lung cancer patients. J Natl Cancer Inst 1990;82:1697-1701.
11. Mizutani Y, Okada Y, Yoshido O, Bonavida B: Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer. Cancer Biother Radiopharm 1996;11:385-391.
12. Gonzalez FM, Vargas JA, Lopez-Cortijo C, Castejon R, Gorriz C, Ramirez-Camacho R, Millan I, Durantez A: Prognostic significance of natural killer cell activity in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 1998;124:852-856.
13. Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K: Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol 2001;96:574-578.
14. Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K: Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 1998;83:58-63.
15. Mizutani Y, Okada Y, Terachi T, Yoshido O: Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer. J Urol 1996;155:892-894.
16. Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V, Prentice HG: Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002;117:821-827.
17. Committee for proprietary medicinal products: Good clinical practice for trials on medicinal products in the European Community; in: The rules governing medicinal products in the European Community vol III. CPMP, Addendum July 1990, pp 57-98.
18. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset publication no 48.Geneva, 1979.
19. Aaronson NK, Cull A, Kaasa S, Sprangers MAG: The EORTC modular approach to quality of life assessment in oncology. J Pain Symptom Manage 1995;10:6-7.
20. Korzeniewski C, Callewaert DM: An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983;64:313-320.
21. Mosman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
22. Kienle GS: Kann die Misteltherapie anhand von Zytokinwirkungen interpretiert werden? Erfahrungsheilkunde 1997;46:494-500.
23. Gabius S, Gabius HJ: Immunmodulierende Misteltherapie durch Lektinstandardisierung: Ein zweischneidiges Schwert? Versicherungsmedizin 1999;51:128-136.
24. Koda K, Saito N, Takiguchi N, Oda K, Nunomura M, Nakajima N: Preoperative natural killer cell activity: Correlation with distant metastases in curatively research colorectal carcinomas. Int Surg 1997;82:190-193.
25. Pross H: Natural killer cell activity in human malignant disease; in Lotzova E, Herberman RB (eds): Natural Immunity, Cancer and Biological Response Modification. Basel, Karger, 1986, pp 196-205.
26. Tartter PI, Steinberg B, Barron DM, Martinelli G: The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 1987;122:1264-1268.
27. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Froedin JE: Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer 2003;105:717-723.
28. Koda K, Saito N, Oda K, Seike K, Kondo E, Ishizuka M, Takiguchi N: Natural killer cell activity and distant metastases in rectal cancers treated surgically with and without neoadjuvant chemoradiotherapy. J Am Coll Surg 2003;197:254-260.
29. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Mayazaki M: Preoperative natural killer cell activity as a prognostic factor for distant metastases following surgery for colon cancer. Dig Surg 2003;20:445-451.
30. Reiche EMV, Nunes SOV, Morimoto HK: Stress, depression, the immune system, and cancer. Lancet Oncol 2004;5:617-625.
31. Garzetti GG, Ciavattini A, Muzzioli M, Goteri G, Mannello B, Romanini C, Fabris N: Natural killer cell activity in patients with invasive cervical carcinoma: Importance of a longitudinal evaluation in follow-up. Gynecol Obstet Invest 1995;40:133-138.
32. Gorelik E, Herberman RB: Role of natural killer (NK) cells in the control of tumor growth and metastatic spread; in Herberman RB (ed): Cancer Immunology: Innovative Approaches to Therapy. New York, Martius Nijhoft Press, 1986, p 151.
33. Aboud M, Kingsmore S, Segal S: Role of natural killer cells in controlling local tumor formation and metastatic manifestation of different 3LL Lewis lung carcinoma cell clones. Nat Immun 1993;12:17-24.
34. Huelsen H, Jilg S, Mechelke E: Einfluss von Mistelpräparaten auf die In vitro-Aktivität der natürlichen Killerzellen von Krebspatienten. Therapeutikon 1992;6:585-588.
35. Huelsen H, Born U: Einfluss von Mistelpräparaten auf die In vitro-Aktivität der natürlichen Killerzellen von Krebspatienten (Teil 2). Therapeutikon 1993;7:434-439.
36. Uchida A, Fukata H: Role of NK cell cytotoxic factor against fresh human tumors. Nat Immun 1993;12:267-278.
37. Klein E, Mantovani A: Action of natural killer cells and macrophages in cancer. Curr Opin Immunol 1993;5:714-718.